PurposeTo evaluate the treatment outcomes of adjunctive photodynamic therapy (PDT) in patients with type 1 choroidal neovascularization (CNV) associated with thickened choroid and refractory to anti‐vascular endothelial growth factor (VEGF) monotherapy.MethodsData on 28 eyes of 28 patients with type 1 CNV with a minimum subfoveal choroidal thickness of 300 μm were reviewed. All showed persistent subretinal and/or intraretinal fluid after at least 4 anti‐VEGF injections in the 6 months before adjunctive PDT. No eyes had certain polypoidal lesions on indocyanine green angiography. The main outcomes measured included the rates of complete fluid absorption at 3 months and the change in best‐corrected visual acuity (BCVA) at 12 months.ResultsAt 3 months, complete fluid absorption was observed in 24 eyes (85.7%). The mean central macular thickness significantly reduced from 342 ± 63 μm to 242 ± 60 μm, and the mean subfoveal choroidal thickness from 386 ± 80 μm to 350 ± 91 μm compared to baseline (P < 0.001, P < 0.001, respectively). Over the 1‐year follow‐up period, 17 eyes (60.7%) were free from recurrent fluid accumulation. Anti‐VEGF injection was mainly used in the re‐treatment of persistent or recurrent exudation (mean: 1.5). At 12 months, the mean BCVA significantly improved compared to baseline (20/53 to 20/44, P = .039), and the logarithm of the minimal angle of resolution BCVA improved by ≥0.3 or maintained in 27 eyes (96.4%).ConclusionsAdjunctive PDT in eyes with type 1 CNV with thickened choroid refractory to anti‐VEGF monotherapy resulted in complete fluid absorption in most eyes, which translated to visual improvement up to 1 year.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.